NCT00552240 - Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2010

Conditions

HIV Infections

Interventions

DRUG

tenofovir DF 300 mg QD

300 mg QD

DRUG

tenofovir DF 300 mg QD

300 mg QD

DRUG

emtricitabine 200 mg QD

200 mg QD

DRUG

emtricitabine 200 mg QD

200 mg QD

DRUG

Nevirapine 200 mg BID

200 mg BID

DRUG

Atazanavir 300 mg

300 mg QD

DRUG

Ritonavir 100 mg

100 mg QD

Trial Locations (19)

Unknown

1100.1512.28 Boehringer Ingelheim Investigational Site, Beverly Hills

1100.1512.20 Boehringer Ingelheim Investigational Site, Los Angeles

1100.1512.15 Boehringer Ingelheim Investigational Site, Denver

1100.1512.26 Boehringer Ingelheim Investigational Site, Washington D.C.

1100.1512.17 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1100.1512.14 Boehringer Ingelheim Investigational Site, Orlando

1100.1512.23 Boehringer Ingelheim Investigational Site, Vero Beach

1100.1512.29 Boehringer Ingelheim Investigational Site, Maywood

1100.1512.11 Boehringer Ingelheim Investigational Site, Neptune City

1100.1512.25 Boehringer Ingelheim Investigational Site, Newark

1100.1512.18 Boehringer Ingelheim Investigational Site, Somers Point

1100.1512.22 Boehringer Ingelheim Investigational Site, Winston-Salem

1100.1512.21 Boehringer Ingelheim Investigational Site, Philadelphia

1100.1512.13 Boehringer Ingelheim Investigational Site, Charleston

1100.1512.30 Boehringer Ingelheim Investigational Site, Dallas

1100.1512.19 Boehringer Ingelheim Investigational Site, Fort Worth

1100.1512.16 Boehringer Ingelheim Investigational Site, Houston

1100.1512.24 Boehringer Ingelheim Investigational Site, Houston

1100.1512.27 Boehringer Ingelheim Investigational Site, Annandale